vs
Marygold Companies, Inc.（MGLD）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
Protalix BioTherapeutics, Inc.的季度营收约是Marygold Companies, Inc.的1.2倍（$9.1M vs $7.6M），Marygold Companies, Inc.净利率更高（-7.5% vs -60.3%，领先52.8%），Marygold Companies, Inc.同比增速更快（-4.5% vs -49.9%），过去两年Marygold Companies, Inc.的营收复合增速更高（-1.5% vs -6.7%）
Marygold Companies, Inc.是一家总部位于美国的多元化控股企业，核心业务覆盖金融服务、特种制造及消费品三大板块，主要面向北美市场开展运营，通过对旗下子公司的战略投资与运营优化实现长期价值增长。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
MGLD vs PLX — 直观对比
营收规模更大
PLX
是对方的1.2倍
$7.6M
营收增速更快
MGLD
高出45.4%
-49.9%
净利率更高
MGLD
高出52.8%
-60.3%
两年增速更快
MGLD
近两年复合增速
-6.7%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $7.6M | $9.1M |
| 净利润 | $-576.0K | $-5.5M |
| 毛利率 | 74.0% | 49.4% |
| 营业利润率 | -8.3% | -51.1% |
| 净利率 | -7.5% | -60.3% |
| 营收同比 | -4.5% | -49.9% |
| 净利润同比 | 67.0% | -184.8% |
| 每股收益（稀释后） | $-0.01 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MGLDPLX
| Q4 25 | $7.6M | $9.1M | ||
| Q3 25 | $7.0M | $17.9M | ||
| Q2 25 | $7.2M | $15.7M | ||
| Q1 25 | $7.0M | $10.1M | ||
| Q4 24 | $8.0M | $18.2M | ||
| Q3 24 | $7.9M | $18.0M | ||
| Q2 24 | $8.3M | $13.5M | ||
| Q1 24 | $7.9M | — |
净利润MGLDPLX
| Q4 25 | $-576.0K | $-5.5M | ||
| Q3 25 | $-356.0K | $2.4M | ||
| Q2 25 | $-1.5M | $164.0K | ||
| Q1 25 | $-1.0M | $-3.6M | ||
| Q4 24 | $-1.7M | $6.5M | ||
| Q3 24 | $-1.6M | $3.2M | ||
| Q2 24 | $-1.9M | $-2.2M | ||
| Q1 24 | $-529.0K | — |
毛利率MGLDPLX
| Q4 25 | 74.0% | 49.4% | ||
| Q3 25 | 77.0% | 53.4% | ||
| Q2 25 | 67.8% | 62.5% | ||
| Q1 25 | 75.0% | 19.1% | ||
| Q4 24 | 74.1% | 78.7% | ||
| Q3 24 | 73.1% | 53.4% | ||
| Q2 24 | 72.5% | 29.8% | ||
| Q1 24 | 70.5% | — |
营业利润率MGLDPLX
| Q4 25 | -8.3% | -51.1% | ||
| Q3 25 | -18.2% | 11.9% | ||
| Q2 25 | -16.5% | 7.5% | ||
| Q1 25 | -21.4% | -41.0% | ||
| Q4 24 | -22.8% | 39.6% | ||
| Q3 24 | -27.4% | 22.2% | ||
| Q2 24 | -33.3% | -18.0% | ||
| Q1 24 | -18.7% | — |
净利率MGLDPLX
| Q4 25 | -7.5% | -60.3% | ||
| Q3 25 | -5.1% | 13.2% | ||
| Q2 25 | -20.4% | 1.0% | ||
| Q1 25 | -14.4% | -35.8% | ||
| Q4 24 | -21.8% | 35.6% | ||
| Q3 24 | -20.1% | 18.0% | ||
| Q2 24 | -22.5% | -16.4% | ||
| Q1 24 | -6.7% | — |
每股收益（稀释后）MGLDPLX
| Q4 25 | $-0.01 | $-0.06 | ||
| Q3 25 | $-0.01 | $0.03 | ||
| Q2 25 | $-0.04 | $0.00 | ||
| Q1 25 | $-0.02 | $-0.05 | ||
| Q4 24 | $-0.04 | $0.10 | ||
| Q3 24 | $-0.04 | $0.03 | ||
| Q2 24 | $-0.05 | $-0.03 | ||
| Q1 24 | $-0.01 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.6M | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $22.7M | $48.2M |
| 总资产 | $27.8M | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MGLDPLX
| Q4 25 | $11.6M | $14.7M | ||
| Q3 25 | $12.5M | $13.6M | ||
| Q2 25 | $12.8M | $17.9M | ||
| Q1 25 | $15.6M | $19.5M | ||
| Q4 24 | $14.9M | $19.8M | ||
| Q3 24 | $17.5M | $27.4M | ||
| Q2 24 | $15.0M | $23.4M | ||
| Q1 24 | $16.1M | — |
股东权益MGLDPLX
| Q4 25 | $22.7M | $48.2M | ||
| Q3 25 | $22.9M | $52.9M | ||
| Q2 25 | $23.0M | $49.9M | ||
| Q1 25 | $24.3M | $45.2M | ||
| Q4 24 | $23.4M | $43.2M | ||
| Q3 24 | $25.5M | $32.4M | ||
| Q2 24 | $26.6M | $28.6M | ||
| Q1 24 | $28.4M | — |
总资产MGLDPLX
| Q4 25 | $27.8M | $82.3M | ||
| Q3 25 | $28.4M | $82.3M | ||
| Q2 25 | $30.4M | $78.5M | ||
| Q1 25 | $33.5M | $73.9M | ||
| Q4 24 | $33.0M | $73.4M | ||
| Q3 24 | $35.9M | $61.6M | ||
| Q2 24 | $32.9M | $91.5M | ||
| Q1 24 | $33.7M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-908.0K | $2.0M |
| 自由现金流经营现金流 - 资本支出 | — | $1.6M |
| 自由现金流率自由现金流/营收 | — | 17.8% |
| 资本支出强度资本支出/营收 | 0.0% | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-13.6M |
8季度趋势，按日历期对齐
经营现金流MGLDPLX
| Q4 25 | $-908.0K | $2.0M | ||
| Q3 25 | $-533.0K | $-3.7M | ||
| Q2 25 | $-3.3M | $-5.2M | ||
| Q1 25 | $-1.2M | $-5.1M | ||
| Q4 24 | $-770.0K | $4.0M | ||
| Q3 24 | $-893.0K | $4.1M | ||
| Q2 24 | $-1.9M | $-3.6M | ||
| Q1 24 | $-658.0K | — |
自由现金流MGLDPLX
| Q4 25 | — | $1.6M | ||
| Q3 25 | $-562.0K | $-4.2M | ||
| Q2 25 | $-3.4M | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | $-776.0K | $3.6M | ||
| Q3 24 | $-940.0K | $4.0M | ||
| Q2 24 | $-2.0M | $-3.8M | ||
| Q1 24 | — | — |
自由现金流率MGLDPLX
| Q4 25 | — | 17.8% | ||
| Q3 25 | -8.1% | -23.7% | ||
| Q2 25 | -46.8% | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | -9.7% | 19.6% | ||
| Q3 24 | -11.9% | 22.4% | ||
| Q2 24 | -23.8% | -28.1% | ||
| Q1 24 | — | — |
资本支出强度MGLDPLX
| Q4 25 | 0.0% | 4.4% | ||
| Q3 25 | 0.4% | 2.8% | ||
| Q2 25 | 0.7% | 2.8% | ||
| Q1 25 | 0.0% | 3.0% | ||
| Q4 24 | 0.1% | 2.3% | ||
| Q3 24 | 0.6% | 0.5% | ||
| Q2 24 | 0.7% | 1.3% | ||
| Q1 24 | 0.0% | — |
现金转化率MGLDPLX
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MGLD
| Fund Management Related Party | $4.6M | 60% |
| Food Products | $1.7M | 22% |
| Beauty Products | $1.2M | 15% |
| Other | $268.0K | 4% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
